# ATOM_local Ablative Therapy

> **NCT01941654** · PHASE2 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 18 (actual)

## Conditions studied

- NSCLC
- Activating EGFR Mutation

## Interventions

- **RADIATION:** preemptive local ablative therapy
- **DRUG:** Oral TKI

## Key facts

- **NCT ID:** NCT01941654
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-18
- **Primary completion:** 2017-12-31
- **Final completion:** 2020-05-28
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941654, "ATOM_local Ablative Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01941654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*